Ignite Creation Date:
2024-05-11 @ 8:28 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06399835
Status:
RECRUITING
Last Update Posted:
2024-05-06
First Post:
2024-04-26
Brief Title:
Enavogliflozin vs Pioglitazone on Glucose and Atherosclerosis
Sponsor:
Seoul National University Bundang Hospital
Organization:
Seoul National University Bundang Hospital
Study Overview
Official Title:
Comparing Enavogliflozin and Pioglitazone as Add-ons to Metformin WithWithout Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 SGLT2 inhibitor regarding various clinical issues including atherosclerosis Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitors Additionally the study will compare changes in other metabolic or cardiovascular risk factors such as triglycerides high density lipoprotein cholesterol HDLc uric acid blood pressure and inflammatory markers between the two drugs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None